Concepedia

Publication | Open Access

Phase I Trial of Pazopanib in Patients with Advanced Cancer

DOIFull Paper Access

411

Citations

18

References

2009

Year

Herbert I. Hurwitz, Afshin Dowlati, Shermini Saini, S. Savage, A. Benjamin Suttle, D. Gibson, Jeffrey P. Hodge, Elmar M. Merkle, Lini Pandite
Clinical Cancer Research

Abstract

Pazopanib was generally well tolerated and showed antitumor activity across various tumor types. A monotherapy dose of 800 mg once daily was selected for phase II studies.

References

YearCitations

Page 1